Cytotoxic effect of Doxorubicin/Menadione combination on human leukemia Jurkat cells

12^th World Cancer Conference

September 26-28, 2016 London, UK

Maria-Teodora Ilie, Ioana Teodora Tofolean, Ramona Babes and Irina Baran

Carol Davila University of Medicine and Pharmacy, Romania

Posters & Accepted Abstracts: J Cancer Sci Ther

Abstract :

The combined cytotoxic effect of the anticancer drug doxorubicin (DOX) and menadione (MD) was assessed in human leukemia Jurkat cells. Oxidative status, apoptosis/necrosis and cell cycle were determined using flow cytometry. Within 4 h of exposure, MD induced oxidative stress and reduced the fraction of viable cells, in a cooperative manner (IC50=11.5 �¼M, Hill coefficient H=2.40). Addition of 0.5 �¼M DOX inhibited the oxidant effect of MD presumably by altering the affinity of MD for respiratory complex I (IC50=22.0 �¼M, H=2.46). In 18-hour treatment, DOX dose-dependently generated significant oxidative stress (IC50=0.6 �¼M, H=2). In combination with 7.5 �¼M and 15 �¼M MD, the oxidative stress generation was increased and DOX cooperativity was enhanced and not modified, respectively. MD induced cell death in a dose-dependent manner (H=2.73) and association with 100 nM DOX enhanced cell death and MD cooperativity (H=5.40). Within 18 h of exposure, DOX induced apoptosis, which was enhanced by 15 �¼M MD. MD dose-dependently altered the cell cycle arrest in G2/M promoted by 100 nM DOX. After a 4 h treatment, both MD and DOX induced mitochondrial depolarization (IC50=6.75 �¼M, H=1.18 and IC50=0.200 nM, H=0.30, respectively). In conclusion, MD could increase the chemotherapeutic potential of doxorubicin.

Biography :

Maria-Teodora Ilie is currently studying Medicine at Carol Davila University of Medicine and Pharmacy and is carrying out research activity in the Department of Biophysics.

Email:mariateodora.ilie@yahoo.com